Indole iminooxy derivatives which inhibit leukotriene biosynthesis

• US 5,399,699 A
• Filed: 01/24/1994
• Issued: 03/21/1995
• Est. Priority Date: 01/24/1994
• Status: Expired due to Fees

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Kolasa, Teodozyi, Bhatia, Pramila, Brooks, Dee W.
• Primary Examiner(s): Springer, David B.
• Application Number:
  US08/186,410
• Time in Patent Office: 421 Days
• Field of Search: 546/273, 546/174, 548/159, 514/314, 514/339, 514/367, 514/365
• US Class Current: 546/174
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 417/12 linked by a chain containing hetero atoms as chain links

Abstract

Compounds of the structure ##STR1## where A₁ is alkylene or cycloalkylene; A₂ is a valence bond, alkylene, or cycloalkylene; R₁ is selected from hydrogen, alkylthio, optionally substituted phenylthio, optionally substituted phenylalkylthio, optionally substituted 2-, 3- and 4-pyridylthio, optionally substituted 2- and 3-thienylthio, and optionally substituted 2-thiazolylthio; R² is selected from optionally substituted phenylalkyl and optionally substituted heteroarylakyl; R³ is selected from alkyl, alkoxy, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted phenylalkyl, optionally substituted phenylalkoxy, optionally substituted naphthyl,optionally substituted naphthyloxy, optionally substituted naphthylalkyl, optionally substituted naphthylalkoxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy; R⁴ is selected from hydrogen and optionally substituted alkyl; and Z is selected from --COOB, --C(OB)R⁶ R⁶, --COOalkyl, --COOalkylaryl, --CONR⁵ R⁶, and --COR⁶ are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment of amelioration of allergic and inflammatory disease states.

Claims

1. A compound having the formula ##STR10## or a pharmaceutically acceptable salt thereof wherein A₁ is alkenylene of one to twelve carbon atoms;

R₁ is alkylthio of one to six carbon atoms;

R₂ is selected from the group consisting of

phenylakyl in which the alkyl portion is of one to six carbon atoms, and

the phenyl group is optionally substituted with up to three substituents selected from the group consisting of

alkyl of one to six carbon atoms,

halogen,

haloalkyl of one to six carbon atoms, and alkoxy of one to twelve carbon atoms;

R₃ is selected from the group consisting of optionally substituted heteroaryl,

wherein the heteroaryl group is selected from the group consisting of

pyridyl,

quinolyl,

thiazolyl,

benzothiazolyl,

wherein the optional substituents on the heteroaryl groups are selected from the group consisting of

alkyl of one to six carbon atoms,

halogen,

alkoxy of one to six carbon atoms, and

haloalkyl of one to six carbon atoms; and

R₄ is selected from the group consisting of

hydrogen, and

alkyl of one to six carbons optionally substituted with hydroxy.

2. A compound or a pharmaceutically acceptable salt thereof as defined by claim 1 selected from the group consisting of

(1-(4-chlorobenzyl)-3-(t-butylthio)-5-(2-quinolinemethoxy))indol-2-yl-(2,2-dimethyl)prop-3-yl-iminooxyacetic acid,

1-(4-chlorobenzyl)-3-(t-butylthio)-5-(2-quinolinemethoxy)indol-2-yl-(2,2-dimethyl)prop-3-yl-iminooxy-2-propionic acid,

1-(4-chlorobenzyl)-3-(t-butylthio)-5-(2-pyridylmethoxy)indol-2-yl-(2,2-dimethyl)prop-3-yliminooxyacetic acid,

1-(4-chlorobenzyl)-3-(t-butylthio)-5-(4-thiazolylmethoxy)indol-2-yl-(2,2-dimethyl)prop-3-yliminooxyacetic acid,

1-(4-chlorobenzyl)-3-(t-butylthio)-5-(4-thiazolylmethoxy)indol-2-yl-(2,2-dimethyl)prop-3-yliminooxy-2-propionic acid,

1-(4-fluorobenzyl)-3-(t-butylthio)-5-(2-quinolinylmethoxy)indol-2-yl-(2,2-dimethyl)prop-3-yliminooxyacetic acid,

1-(4-chlorobenzyl)-3-(t-butylthio)-5-(2-quinolinylmethoxy)indol-2-ylmethyliminooxyacetic acid,

1-(4-chlorobenzyl)-3-(t-butylthio)-5-(2-quinolinylmethoxy)indol-2-ylmethyliminooxy-2-propionic acid, and

1-(4-chlorobenzyl)-3-(t-butylthio)-5-(2-benzothiazoylmethoxy)indole-(2,2-dimethyl)prop-3-yliminooxyacetic acid.

3. A pharmaceutical composition for inhibiting the biosynthesis of leukotrienes comprising a therapeutically effective amount of a compound as defined by claim 1 in combination with a pharmaceutically acceptable carrier.

4. A method of inhibiting the biosynthesis of leukotrienes comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound as defined by claim 1.